Literature DB >> 34935436

Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.

Margarita V Rangel1, Nicole McAllister2,3, Kristen Dancel-Manning4, Maria G Noval1, Laurie A Silva5,3, Kenneth A Stapleford1.   

Abstract

Chikungunya virus (CHIKV) is a reemerging arthropod-borne alphavirus and a serious threat to human health. Therefore, efforts toward elucidating how this virus causes disease and the molecular mechanisms underlying steps of the viral replication cycle are crucial. Using an in vivo transmission system that allows intrahost evolution, we identified an emerging CHIKV variant carrying a mutation in the E1 glycoprotein (V156A) in the serum of mice and saliva of mosquitoes. E1 V156A has since emerged in humans during an outbreak in Brazil, cooccurring with a second mutation, E1 K211T, suggesting an important role for these residues in CHIKV biology. Given the emergence of these variants, we hypothesized that they function to promote CHIKV infectivity and subsequent disease. Here, we show that E1 V156A and E1 K211T modulate virus attachment and fusion and impact binding to heparin, a homolog of heparan sulfate, a key entry factor on host cells. These variants also exhibit differential neutralization by antiglycoprotein monoclonal antibodies, suggesting structural impacts on the particle that may be responsible for altered interactions at the host membrane. Finally, E1 V156A and E1 K211T exhibit increased titers in an adult arthritic mouse model and induce increased foot-swelling at the site of injection. Taken together, this work has revealed new roles for E1 where discrete regions of the glycoprotein are able to modulate cell attachment and swelling within the host. IMPORTANCE Alphaviruses represent a growing threat to human health worldwide. The reemerging alphavirus chikungunya virus (CHIKV) has rapidly spread to new geographic regions in the last several decades, causing overwhelming outbreaks of disease, yet there are no approved vaccines or therapeutics. The CHIKV glycoproteins are key determinants of CHIKV adaptation and virulence. In this study, we identify and characterize the emerging E1 glycoprotein variants, V156A and K211T, that have since emerged in nature. We demonstrate that E1 V156A and K211T function in virus attachment to cells, a role that until now has only been attributed to specific residues of the CHIKV E2 glycoprotein. We also demonstrate E1 V156A and K211T increase foot-swelling of the ipsilateral foot in mice infected with these variants. Observing that these variants and other pathogenic variants occur at the E1-E1 interspike interface, we highlight this structurally important region as critical for multiple steps during CHIKV infection. Together, these studies further define the function of E1 in CHIKV infection and can inform the development of therapeutic or preventative strategies.

Entities:  

Keywords:  Alphavirus; chikungunya virus; emergence; glycoprotein; inflammation

Mesh:

Substances:

Year:  2021        PMID: 34935436      PMCID: PMC8865554          DOI: 10.1128/JVI.01586-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  60 in total

1.  Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection.

Authors:  Atsushi Tanaka; Uranan Tumkosit; Shota Nakamura; Daisuke Motooka; Natsuko Kishishita; Thongkoon Priengprom; Areerat Sa-Ngasang; Taroh Kinoshita; Naokazu Takeda; Yusuke Maeda
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

2.  Inhibition of the vacuolar H(+)-ATPase with bafilomycin reduces delivery of internalized molecules from mature multivesicular endosomes to lysosomes in HEp-2 cells.

Authors:  B van Deurs; P K Holm; K Sandvig
Journal:  Eur J Cell Biol       Date:  1996-04       Impact factor: 4.492

3.  Evolution-Driven Attenuation of Alphaviruses Highlights Key Glycoprotein Determinants Regulating Viral Infectivity and Dissemination.

Authors:  Maria G Noval; Bruno A Rodriguez-Rodriguez; Margarita V Rangel; Kenneth A Stapleford
Journal:  Cell Rep       Date:  2019-07-09       Impact factor: 9.423

4.  Chikungunya virus arthritis in adult wild-type mice.

Authors:  Joy Gardner; Itaru Anraku; Thuy T Le; Thibaut Larcher; Lee Major; Pierre Roques; Wayne A Schroder; Stephen Higgs; Andreas Suhrbier
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 5.  A structural and functional perspective of alphavirus replication and assembly.

Authors:  Joyce Jose; Jonathan E Snyder; Richard J Kuhn
Journal:  Future Microbiol       Date:  2009-09       Impact factor: 3.165

6.  Genetic characterization of Chikungunya virus from New Delhi reveal emergence of a new molecular signature in Indian isolates.

Authors:  Jatin Shrinet; Shanu Jain; Anil Sharma; Shashi Shekhar Singh; Kalika Mathur; Vandita Rana; Raj K Bhatnagar; Bhupendra Gupta; Rajni Gaind; Monorama Deb; Sujatha Sunil
Journal:  Virol J       Date:  2012-05-25       Impact factor: 4.099

7.  Membrane protein lateral interactions control Semliki Forest virus budding.

Authors:  M Ekström; P Liljeström; H Garoff
Journal:  EMBO J       Date:  1994-03-01       Impact factor: 11.598

Review 8.  Glycosaminoglycan-Protein Interactions and Their Roles in Human Disease.

Authors:  Deling Shi; Anran Sheng; Lianli Chi
Journal:  Front Mol Biosci       Date:  2021-03-09

9.  Epidemiology of Chikungunya in the Americas.

Authors:  Sergio Yactayo; J Erin Staples; Véronique Millot; Laurence Cibrelus; Pilar Ramon-Pardo
Journal:  J Infect Dis       Date:  2016-12-15       Impact factor: 5.226

10.  Chikungunya Virus Strains from Each Genetic Clade Bind Sulfated Glycosaminoglycans as Attachment Factors.

Authors:  Nicole McAllister; Yan Liu; Lisete M Silva; Anthony J Lentscher; Wengang Chai; Nian Wu; Kira A Griswold; Krishnan Raghunathan; Lo Vang; Jeff Alexander; Kelly L Warfield; Michael S Diamond; Ten Feizi; Laurie A Silva; Terence S Dermody
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.